Stockwinners Market Radar for December 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:10 EST Acropolis Infrastructure to redeem shares, will not enter business combination - Acropolis Infrastructure Acquisition announced that it will liquidate and dissolve the Company in accordance with the provisions of the Company's amended and restated certificate of incorporation, as amended. Accordingly, the Company will redeem all outstanding shares of Class A common stock, par value $0.0001, effective as of December 19, 2023. The per share redemption price for the public shares will be approximately $10.49, less amounts required to pay the Company's tax obligations. The balance of the trust account as of December 4, 2023 was approximately $84,040,779.58, which includes approximately $4,032,789.58 in interest income. In accordance with the terms of the related trust agreement, the Company expects to retain up to $100,000 of the interest income from the trust account to pay dissolution expenses and amounts required to pay the Company's tax obligations. Prior to the withdrawal of amounts required to pay the Company's tax obligations, there is expected to be a total of approximately $83,940,779.58 available for redemption of the 8,000,799 public shares outstanding.

20:02 EST Cathie Wood's ARK Investment bought 136.6K shares of PagerDuty today

19:11 EST Rockstar says 'GTA VI' coming to PS5, Xbox Series X/S in 2025 - Rockstar Games, a publishing label of Take-Two (TTWO), announced that "Grand Theft Auto VI" is coming to PlayStation 5 (SONY) and Xbox Series X/S (MSFT) consoles in 2025. "Grand Theft Auto VI continues our efforts to push the limits of what's possible in highly immersive, story-driven open-world experiences," said Sam Houser, Founder of Rockstar Games. "We're thrilled to be able to share this new vision with players everywhere." "Grand Theft Auto VI" is not yet rated, the studio noted.

18:55 EST Meta Platforms CEO Zuckerberg sells $9.1M in two separate transactions - In regulatory filings, Meta Platforms disclosed that its CEO Mark Zuckerberg sold $9.1M in each of two separate transactions as part of an option expiry on November 30th and December 1st.

18:50 EST Marvell CEO: We have a great set up for AI next year - In an interview on CNBC's Mad Money, Matt Murphy said Marvell has a great set up for AI in 2024 and it's targeting $200M in AI revenue per quarter. "We have great excitement around the data center business for 2024," he added. "AI is a portion of the data center business, but it's the fastest growing segment." He expects the data center business to account for about 50% of the company's revenue in Q4.

18:36 EST Vaxcyte says VAX-24 proof-of-concept results published in The Lancet - Vaxcyte announced the publication of the results from the VAX-24 Phase 1/2 clinical proof-of-concept study in the journal The Lancet Infectious Diseases. This study evaluated the safety, tolerability and immunogenicity of Vaxcyte's investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine compared to the current standard-of-care, Prevnar 20, for the prevention of invasive pneumococcal disease in healthy adults 18-64 years of age. The study results showed VAX-24 demonstrated a safety and tolerability profile that was comparable to PCV20 at all doses studied, and an immunogenicity profile that met or exceeded established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The Company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program. "The publication of our data in The Lancet Infectious Diseases, which is also highlighted in an independent commentary, is a testament to the potential of our cell-free technology to create carrier-sparing conjugate vaccines that provide broader coverage with enhanced immunogenicity compared to the standard-of-care in adults today," said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. "Despite the availability of pneumococcal vaccines, the bacteria associated with IPD continues to be a major driver of deaths as a result of antimicrobial resistance. This is among the many reasons why the public health community continues to affirm the need for new vaccines that provide broader coverage against this disease. We believe these proof-of-concept study results underscore the potential of VAX-24 to address this important public health need."

18:12 EST Rockstar says 'Grand Theft Auto VI' to release in 2025 - Take-Two's Rockstar Games announced in the first trailer for "Grand Theft Auto VI" that the game will release in 2025. Reference Link

17:58 EST Arco Platform announces shareholder approval of go-private deal - Arco Platform Limited announced that at an extraordinary general meeting of shareholders held today, Arco's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of August 10, 2023, among the company, Achieve Holdings and Achieve Merger Sub, a wholly owned subsidiary of Achieve. The plan of merger is required to be filed with the Registrar of Companies of the Cayman Islands upon completion of the Merger. Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the Merger, Merger Sub will merge with and into the Company and cease to exist, with Arco being the surviving company and becoming a wholly-owned subsidiary of Achieve. Approximately 81.5% of Arco's total outstanding Class A common shares and Class B common shares, par value $0.00005 per share, attended the extraordinary general meeting in person or by proxy. Each shareholder has one vote for each Class A Share and/or 10 votes for each Class B Share. The Merger Agreement, the Plan of Merger, and the transactions contemplated thereby, including the Merger, were approved by over 97.8% of the total votes cast at the extraordinary general meeting.

17:49 EST ExpressVPN launches Apple TV app - ExpressVPN announced the all-new ExpressVPN app for Apple TV. "To get started, simply visit the App Store on your Apple TV, download the ExpressVPN app, and sign in to your account," the company said. "That's it. Now you're ready to connect to a server location in any of 105 countries around the world, all from the comfort of your couch. Even signing in is a snap: Just scan a QR code with your phone or enter your details with your remote control, and you're in."

17:25 EST RTX awarded $321.27M USSOCOM contract - RTX was being awarded a single award, firm-fixed-price, multi-year contract in the amount of $321.27M for the continued production and delivery of Silent Knight Radar systems and initial spare components in support of Special Operations Command, or USSOCOM. The work will be performed primarily at contractor locations in McKinney, Texas; and Forest, Mississippi, and is expected to be completed by December 31, 2028. Foreign Military Sales funding of $27.5M will be used. Solicitation for Silent Knight Radars was issued sole-source to Raytheon Co. under authority of 10 U.S. Code 2304, as implemented in Federal Acquisition Regulation 6.302-1 and detailed in approved Justification and Analysis 22-2147. USSOCOM is the contracting activity.

17:12 EST NewMarket to acquire AMPAC Intermediate Holdings for about $700M - NewMarket announced its entry into a definitive purchase agreement to acquire AMPAC Intermediate Holdings, the ultimate parent company of American Pacific Corporation, for approximately $700M. Based in Cedar City, Utah, AMPAC is a North American manufacturer of critical performance additives used in solid rocket motors for space launch and military defense applications. AMPAC is qualified on many NASA and Department of Defense programs, and has been serving space launch and national defense programs for more than 60 years. AMPAC also manufactures Halotron BrX, a clean and environmentally friendly fire extinguishing agent that replaces legacy high ozone-depleting fire extinguishing agents. Founded in 1955, AMPAC has one operating facility and approximately 150 full-time employees. The transaction is expected to close during the first quarter of 2024. The closing is conditioned upon the satisfaction or waiver of customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. NewMarket expects to finance the acquisition with available cash and borrowings under its revolving credit facility.

17:01 EST Hayward names John Collins as Chief Commercial Officer - Hayward Holdings announced the promotion of John Collins to Chief Commercial Officer, effective immediately. In his new role, John will lead the company's sales, marketing, customer service and product management teams in North America, as well as the global industrial Flow Control business. Collins has served as Hayward's Senior Vice President and Chief Supply Chain Officer since May 2022. Prior to joining Hayward, Collins was the Senior Vice President and General Manager of E-Z-GO for Textron Specialized Vehicles.

16:52 EST GitLab jumps 14% to $60.65 after Q3 earnings beat, guidance raise - Shares of GitLab are up 14% or $7.72 at $60.65 after its Q3 earnings beat and guidance raise for FY24.

16:44 EST Hillenbrand director buys $249.4K in common stock - In a regulatory filing, Hillenbrand disclosed that its director Helen Cornell bought 6.5K shares of common stock on November 30th in a total transaction size of $249.4K. Shares of Hillenbrand are up 0.9% afterhours at $40.55.

16:39 EST The Hanover raises quarterly dividend by 5% to 85c per share - The dividend is payable December 29, 2023, to shareholders of record at the close of business on December 15, 2023. CEO John Roche stated: "We are pleased to announce a 5% increase in our quarterly dividend, highlighting our board's confidence in the overall financial strength of our company and our prospects. This dividend increase will mark our 19th consecutive annual dividend increase. Looking ahead to 2024, we are well positioned to deliver positive results as we execute on our go-forward strategy while remaining committed to being responsible stewards of our capital."

16:36 EST Black Hills files rate review app with Arkansas Public Service Commission - Black Hills announced that its Arkansas natural gas utility, Black Hills Energy Arkansas, doing business as Black Hills Energy, filed a rate review application with the Arkansas Public Service Commission requesting $44.1M in new annual revenue. Black Hills Energy has invested approximately $130 M in safety, system integrity and reliability for more than 7,200 miles of natural gas pipeline infrastructure in Arkansas since its last general rate filing in 2021. These critical investments were required to support and extend service to approximately 7,500 new customers in the rapidly growing communities in the state, to ensure the safe and reliable delivery of natural gas to all customers' homes and businesses, and to meet compliance requirements of state and federal regulations. "We are committed to safe and reliable service as we support the vibrant economic growth in our Arkansas communities," said Linn Evans, president and CEO of Black Hills Corp. "This rate review request consists of the critical investments we have made to maintain system integrity and serve growth and reflects the increased costs of serving our customers driven by inflation and higher interest rates." As proposed, the rate review is requesting a capital structure of 48% equity and 52% debt and a return of equity of 10.5% for investments the company has made in its natural gas system in Arkansas. Black Hills Energy is seeking to implement new rates in the fourth quarter of 2024.

16:33 EST Lesaka says CEO Chris Meyer to conclude tenure, Ali Mazanderan to become chair - Lesaka announced that Chris Meyer will conclude his tenure as Lesaka Group CEO on February 29, 2024. During his nearly three years as group CEO, Meyer has led the successful turnaround and building of the Lesaka fintech platform. Meyer will remain a director of Lesaka. Ali Mazanderani will assume the executive chairman role on February 1, 2024.

16:32 EST Tegna CEO Lougee sells 100,000 common shares - In a regulatory filing, Tegna president and CEO David Lougee disclosed the sale of 100,000 common shares of the company on November 30 at a price of $15.38 per share.

16:30 EST Robinhood says customers contributed $1.4B of net deposits in November - Robinhood disclosed that in November, customers contributed roughly $1.4B of net deposits to Robinhood. Additionally, November equity notional trading volumes and options contracts traded were roughly in line with October levels, and November crypto notional trading Volumes were roughly 75% above October levels, the company said in a regulatory filing. The Company plans to release its full November 2023 Operating Data in the coming weeks.

16:29 EST Ceridian appoints Jeremy Johnson as CFO, Justine Janssen as CSO - Ceridian announced the appointments of Jeremy Johnson as executive VP and CFO, effective January 1, 2024, and Justine Janssen as executive VP and chief strategy officer , or CSO, effective immediately. Johnson and Janssen are both former Ceridian executives, returning in new roles. Both roles report directly into David Ossip, chair and CEO. Johnson will succeed Noemie Heuland who, as previously announced, will cease serving as Ceridian's CFO after December 31. With Johnson's assumption of the CFO role, Heuland will move into a senior advisory role to support a transition.

16:25 EST ADDvantage receives noncompliance notification from Nasdaq - ADDvantage announced that it received a notification letter from the Listing Qualifications Department of Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550.

16:22 EST PAVmed announces 1-for-15 reverse stock split - PAVmed (PAVM) announced a dividend of approximately 3.3M shares of common stock of its majority-owned subsidiary, Lucid Diagnostics (LUCD), which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid. PAVmed shareholders as of January 15, 2024, will participate in the dividend distribution. PAVmed also announced that it will conduct a 1-for-15 reverse stock split of its own common stock. The PAVmed Board of Directors has declared a dividend of approximately 3.3M shares of Lucid common stock with a record date of January 15, 2024. All holders of PAVmed capital stock as of such date will participate in the dividend on a pro rata basis. Contemporaneous with the dividend, Lucid will issue to PAVmed an equivalent number of shares of Lucid common stock as payment for the portion of intercompany debt owed to PAVmed that Lucid incurred during fiscal year 2022. As a result, the number of shares of Lucid common stock held by PAVmed will remain unchanged following the distribution.

16:20 EST Essential Properties Realty raises quarterly dividend by 1.8% to 28.5c per share - The dividend is payable on January 12, 2024 to stockholders of record as of the close of business on December 29, 2023.

16:12 EST Openlane to acquire Manheim Canada for about $95M - Openlane has signed a definitive agreement to acquire the Manheim Canada business from Cox Automotive, subject to certain customary closing conditions. The proposed acquisition advances OPENLANE's digital strategy by adding Manheim Canada inventory, buyers, sellers and corresponding data to the OPENLANE Canada digital marketplace launched earlier this year. Valued at approximately $95M, the transaction includes the Manheim Montreal facility and auction sales, operations and select staff across Manheim Canada, which intends to exit Canada. Under the agreement, OPENLANE will assume Manheim Canada's customer relationships. After the transaction closes, OPENLANE will integrate the Manheim Canada business into the existing OPENLANE Canada business, combining all inventory within the OPENLANE digital marketplace.

16:09 EST Landstar System names Frank Lonegro CEO, effective February 2 - Landstar System (LSTR) announced that its Board of Directors has named Frank A. Lonegro as President and Chief Executive Officer, effective February 2. James B. Gattoni, who currently serves as President and CEO, will continue to serve in that role through the date of the Company's 2023 fourth quarter earnings release conference call, currently scheduled for February 1, following which he will be transitioning to the role of Special Advisor to the CEO before his anticipated retirement in July 2024. Mr. Lonegro will also be appointed to the Board of Directors of Landstar System as of his commencement as CEO, succeeding Mr. Gattoni who will be stepping down from the Board as of February 2. Lonegro is joining Landstar from Beacon Building Products (BECN), where he currently serves as Executive Vice President and Chief Financial Officer. Beacon is a Fortune 500 building products distribution company serving customers throughout the U.S. and Canada. Prior to working at Beacon, Mr. Lonegro worked for almost 20 years at CSX Corporation, a Fortune 250 rail transportation company headquartered in Jacksonville, Florida. During his long tenure at CSX, Mr. Lonegro served in a number of capacities, including Executive Vice President and Chief Financial Officer from 2015 to 2019, as well as key technology and operational roles earlier in his tenure, including President of CSX Technology, Vice President of Service Design, and Vice President of Mechanical."Frank's broad financial, operational and technology leadership at large, publicly traded organizations make for an outstanding fit at Landstar," said Chairman of the Board Diana Murphy. "The Board is delighted to welcome Frank and his impressive record of achievement to Landstar. On behalf of the independent members of the Board, I also want to express tremendous appreciation to Jim for his leadership of Landstar and partnership with all of us."

16:08 EST Altisource Asset Management receives communications from NYSE - Altisource Asset Management Corporation announced that on November 30, 2023, the company received a written notice from the New York Stock Exchange that the NYSE would delist the company's shares of common stock from the Exchange. NYSE Regulation staff has determined that the company is no longer qualified for listing pursuant to Section 1009(a) of the NYSE American Company Guide, citing non-compliance with Sections 1003(a)(i), (ii) and (iii) thereof. The company has a right to appeal this determination, provided that it files a written request for such review within seven calendar days after receiving the Notice. The company's board of directors intends to exercise its right to appeal the NYSE Regulation staff's determination by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. Following such appeal and a decision by the Panel, NYSE American or the company will make an announcement regarding either delisting or continued trading of the company's common stock. There can be no assurance of the outcome of any such appeal or that the Exchange will reconsider its decision to delist the company in light of such appeal.

16:06 EST Purple Innovation announces positive Black Friday/Cyber Monday weekend - Purple Innovation announced positive year-over-year sales results for the Black Friday through Cyber Monday period (November 24-27, 2023) and reiterated its 2023 full year outlook. "The momentum that has been building in our business since the launch of our Path to Premium Sleep strategy earlier this year has accelerated in the fourth quarter, most notably over the key Black Friday / Cyber Monday long weekend," said CEO Rob DeMartini. "This was the first key holiday selling period when our new product portfolio and enhanced brand positioning were fully deployed across all distribution channels and all doors, and the results were positive. For the four days following Thanksgiving, we achieved high teens and high single-digit sales gains in our showroom channel and our eCommerce channel, respectively, and the sell-through feedback we received from our wholesale partners indicate that our balance of share was up meaningfully. Importantly, overall demand for our highest priced mattresses was strong, underscoring the traction we are making evolving Purple into a formidable player in the premium and luxury sleep space."

16:05 EST Sonic Foundry announces delisting from Nasdaq - Sonic Foundry "announced that the Company received a final delisting notice from Nasdaq on December 1, 2023. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on December 5, 2023."

16:02 EST Franklin Electric acquires assets of Action Manufacturing & Supply, no terms - Franklin Electric announced that its wholly owned subsidiary, Franklin Water Treatment has acquired the assets of Action Manufacturing & Supply, a manufacturer and wholesale distributor of residential water conditioning, filtration, and indoor/outdoor aeration systems since 1980 with operations in Florida and North Carolina. The operating results of the acquired business will be reported in the company's Water Systems business segment. Don Line, President of Franklin Water Treatment commented: "We are excited to incorporate the business of Action Manufacturing & Supply into our existing business as we continue to strengthen and expand our channels and products in key geographic areas for water treatment. Action's commitment to quality and reputation for service excellence aligns with Franklin's customer-driven approach to our businesses." Franklin Water Treatment, provides products, services, and system solutions for residential, commercial, and industrial point of use and point of entry water treatment products, in a wide variety of markets and applications.

15:54 EST Correction: AstraZeneca is not scheduled to report earnings tomorrow - A prior note that had been tagged with the symbol for AstraZeneca (AZN) recounting the companies scheduled to report earnings before tomorrow's open was issued in error.

15:24 EST Curio Bioscience to 'vigorously defend' against 10x Genomics' allegations - The company stated, "Curio Bioscience is a leading innovator of high-precision tools for the life sciences industry. Our Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution and represents the next stage of innovation from our team's inventions of the microarray, stochastic barcoding (unique molecular identifiers), and single cell and spatial tagging and analysis. Our team's inventions of spatial localization of biological targets using barcoding were documented over 15 years ago. We believe that fair competition is a key component to innovation, and we embrace the motivation that it provides for creating the newest and highest-performing products for our customers, while keeping experiment costs reasonable and pushing the frontiers of science to the greatest extent possible. Some companies do not share this sentiment. We have become the latest target in a string of attacks by a company,10x Genomics, with a history of bringing litigation against smaller, innovating companies. We are confident that we do not infringe the patents that 10x is asserting against us and believe that they will be found invalid. We will vigorously defend against 10x's allegations."

14:07 EST IBM, Palo Alto Networks announce expanded strategic partnership - IBM (IBM) Consulting and Palo Alto Networks (PANW) announced that they will expand their strategic partnership to "better enable clients to strengthen their end-to-end security postures and navigate evolving security threats." The companies said "Palo Alto Networks, a global cybersecurity leader, will be in a select group of strategic IBM Consulting partners and IBM Consulting will be a premier security services partner for Palo Alto Networks... As part of this relationship, the companies will jointly offer enhanced security solutions delivered by IBM Consulting Cybersecurity Services, integrating Palo Alto Networks security technologies. The expanded partnership will initially focus on two key areas: helping companies modernize their security operations and securing cloud transformations."

13:06 EST RTX secures $8M DARPA contract from Department of Defense - RTX will help the Department of Defense address systemic risk in the procurement and delivery of supplies under an $8 million DARPA contract. The work will be performed by the company's Raytheon BBN Technologies unit. Under the Resilient Supply-and-Demand Networks contract, Raytheon BBN will develop a robust modeling and simulation tool that uses historical and behavioral survey data to predict the impact of and develop mitigations for shocks to supply demand networks. This is the first global supply chain stress test framework created for this purpose.

12:32 EST Gaia launches artificial intelligence powered search engine - Gaia announced the launch of a new artificial intelligence powered search engine. The engine is "trained on categorical metadata and transcripts, unlocking the power of the world's largest transformational conscious media library of over 10,000 titles in English, Spanish, French and German," the company said in a statement. It added, "Members can now enter natural language queries related to their transformational interests and quickly uncover the most relevant films, series episodes, yoga classes, or documentary content to stream. As Gaia's AI technology continues learning users' preferences, it delivers increasingly tailored recommendations over time. This continues the brand's focus on establishing itself as the world's leading player in the conscious and transformative media space."

12:30 EST IXHL Stock trading resumes

12:20 EST Maison Solutions Inc trading resumes

12:15 EST Maison Solutions Inc trading halted, volatility trading pause

12:00 EST Miniso falls -11.1% - Miniso is down -11.1%, or -$2.69 to $21.55.

12:00 EST Annovis Bio rises 10.4% - Annovis Bio is up 10.4%, or 88c to $9.37.

12:00 EST Beachbody Company rises 11.3% - Beachbody Company is up 11.3%, or 83c to $8.26.

11:43 EST Honest Company broadens partnership with Tinuiti - Tinuiti, an independent performance marketing firm across Streaming TV, Google, Meta, and Amazon, has expanded its scope of work with The Honest Company. As The Honest Company's official Paid Media Agency, Tinuiti currently oversees the business' Paid Search, Shoppable Media, Paid Social, Affiliate, Marketplaces, and Analytics. Erin Thoensen, Vice President, General Manager Baby + Home at The Honest Company, said: "As we grow in our partnership with Tinuiti we're excited to leverage our teams' shared expertise and the collaboration that we've established over the years. Together, we've been able to create efficiencies, while also identifying weaknesses, allowing us to navigate to creative and innovative solutions- and that has been a recipe for success. We feel confident this partnership will continue to carry us into the future successfully."

11:03 EST iShares Industrials Sector Bond Fund trading resumes

10:07 EST Bumble adds 'Plans', AI-powered conversation starters to Bumble For Friends - Bumble For Friends adds two notable updates, AI-generated conversation starters and Plans, to get offline and make local friends. Bumble For Friends is rolling out a highly-requested feature known as Plans, which helps members meet IRL with groups of up to 15 people. Whether you're planning a monthly book club or seeking concert buddies, Plans simplifies the process of organizing and participating in group get-togethers. For anyone navigating being new to an area or starting afresh, finding like-minded individuals to do things with can be a challenge; Plans on Bumble For Friends helps solve that problem by facilitating connections to nearby group activities. Additionally, Bumble For Friends is making it faster to get conversations going with new friends. Powered by artificial intelligence, Bumble For Friends' new personalized conversation starters assist with crafting the perfect icebreaker to initiate a conversation. This feature is currently available in English.

10:03 EST Safe & Green enters into contribution agreement to form JV - Safe & Green Holdings (SGBX) announced that its subsidiary, Safe and Green Development Corporation (SGD), has agreed to enter into a contribution agreement with an affiliate of MNO Partners to form a joint venture to develop the Lago Vista property. The cost to fully develop the property is estimated to be approximately $80M, which includes the development of the project from conception to completion. The Lago Vista property was originally purchased by SG DevCo's subsidiary for $3.5M in 2021. Pursuant to the terms of a Contribution Agreement, SG DevCo's subsidiary will contribute the property to the JV and receive as consideration for the property contribution a membership interest in the JV valued at $11.5M. MNO Partners will lead the development process and, after the completion of the feasibility period, will be required to submit permits for the first phase of the project within 11 months from the execution of the Contribution Agreement. It is anticipated that the JV will secure construction financing, which is a condition to the closing of the JV. The primary focus during the early stages of design include luxury condos and the marina. David Villarreal, President & CEO of Safe and Green Development Corporation, stated, "We are excited about this partnership as we're making progress and aiming to develop the project to serve as a model of sustainable, community-focused development amid our portfolio. Our JV partner will be contributing financial resources to the development of this project. Their financial commitment to the project strengthens our joint capacity to execute successfully and deliver on the project. The initial estimate for the total project cost is approximately $80M. We believe this collaboration will generate significant value for SG DevCo and its stockholders."

09:56 EST HUB Security names Noah Hershcoviz as new CEO - HUB's board has unanimously appointed Noah Hershcoviz as the new CEO. Noah currently serves as the company's Chief Strategy Officer and a member of its Board of Directors, and his deep understanding of the company's vision and his strategic acumen position him as an exceptional candidate to lead HUB Security into its next growth phase. His appointment is effective immediately. Noah was formerly a member of the EY Transaction Advisory team and has global banking and business experience with multi-billion-dollar international public companies and IPOs. Simultaneously, Uzi Moscovich, who was the Chairman of the Board up till 11 months ago, and played a crucial role in navigating HUB Security through multiple challenges and restoring stability following the termination of the previous CEO, will be assuming back the role of Active Director on the board.

09:47 EST Biotie Therapies falls -7.1% - Biotie Therapies is down -7.1%, or -$1.02 to $13.34.

09:47 EST Alaska Air falls -17.9% - Alaska Air is down -17.9%, or -$7.10 to $32.63.

09:47 EST Spotify rises 9.0% - Spotify is up 9.0%, or $16.26 to $196.95.

09:41 EST Garden Stage Ltd trading resumes

09:39 EST Clean Earth Acquisitions Corp trading resumes

09:37 EST WidePoint's IT Authorities awarded $216,000 contract from healthcare provider - WidePoint Corporation announced that its subsidiary IT Authorities has been awarded a new three-year contract initially valued at $216,000 from a mobile healthcare provider.

09:36 EST Knightscope hires Basile Law to investigate activities around stock performance - Knightscope has retained attorney Mark R. Basile and his short and distort securities litigation firm, The Basile Law Firm P.C., to investigate recent activities surrounding the Company's stock performance and to take whatever legal action necessary to prevent potential market participants from utilizing unlawful means to further hurt retail investors, including the recently published research papers by Capybara Research.

09:34 EST DDC Enterprise board approves share repurchase program up to 500,000 shares - DDC Enterprise announces that its Board of Directors approved a 10b-18 share repurchase program with authorization to purchase up to 500,000 of the Company's Class A Ordinary Shares. This plan is effective immediately for up to a one-year period.

09:32 EST GT Biopharma announces IND submission for GTB-3650 - GT Biopharma announced the submission of an Investigational New Drug application with the FDA for the development of GTB-3650, a 2nd generation nanobody TriKE for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome.

09:31 EST Garden Stage Ltd trading halted, volatility trading pause

09:30 EST Dune Acquisition Corp trading halted, volatility trading pause

09:22 EST Twilio to end-of-life Twilio Programmable Video as standalone product - The company said: "Given it's such a niche area and a relatively small part of our portfolio, we believe partnering with video industry leaders is the best way to ensure long-term product innovation for our customers. Removing Programmable Video from our portfolio will also allow Communications to more effectively focus on our pillar products - Messaging, Voice, and Email."

09:19 EST Twilio CEO says has 'underachieved' on growth in TD&A - In a letter to employees, Twilio CEO Jeff Lawson said the company has underachieved on growth in TD&A, "so we're taking some steps to create a more effective GTM motion for Flex and recalibrate our investments in Segment, which combined will unfortunately mean parting ways with approximately 5% of Twilio's workforce." Lawson said: "The decision to eliminate these roles was a hard one, but we're confident it's in the best interest of our customers and the long-term health of our business. At the same time, we're opening up more AE roles inside of Communications and I encourage all sellers impacted by these changes to apply."

09:18 EST Ford reports November U.S. sales down 0.5% to 145,559 vehicles - Ford reports total November U.S. sales of 145,559 vehicles, down 0.5% from 146,364 last year. Ford reports U.S. electric vehicle sales of 8,958 in November, up 43.2%, hybrid vehicle sales of 12,108, up 75.2% and internal combustion vehicle sales of 124,493, down 6.5% from the same month of last year. Reference Link

09:17 EST TMT Acquisition enters merger agreement with eLong Power - TMT Acquisition Corpand eLong Power Holding announced that they have entered into a definitive business combination agreement, dated December 1, 2023, that will result in eLong Power becoming a publicly traded company. Huizhou Yipeng Energy Technology Co., is the operating entity of eLong Power. Upon the closing of the transaction, the combined company is expected to be named eLong Power Inc. and its securities are expected to be listed on the Nasdaq Stock Exchange. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024. The Company, founded in 2014, develops disruptive battery technologies for commercial and specialty vehicles as well as energy storage systems, with research and development and production capabilities that span multiple battery cell chemistries, modules and packs. The Company's lower-cost, high power and fast-charging batteries are designed specifically for commercial electric vehicles and large-scale energy storage system. The Company's battery solutions are powered by its broad, proprietary intellectual property portfolio, which is fully owned and protected by numerous patents and other intellectual properties. Due to its highly differentiated, vertically integrated R&D and industrialization system, the Company believes it delivers faster product development, tighter cost control and greater customization to its customers than does its competitors. As a result, the Company is supported by marquee strategic partnerships with industry leaders. The business combination transaction with TMTC is expected to provide the Company with access to the U.S. public equity markets and thereby accelerate its business expansion and position the Company to explore additional growth and value creating opportunities. Pursuant to the proposed business combination agreement, a subsidiary of TMTC will be merged with and into eLong Power, the result of which eLong Power will become a wholly-owned subsidiary of TMTC, with the newly combined publicly traded company to be named eLong Power Inc. In the transaction, all shares of eLong Power would be converted into ordinary shares of the newly combined entity. As a result, upon closing, eLong Power's shareholders would receive 45,000,000 ordinary shares of the new eLong Power Inc., which, at an implied value of $10.00 per share, would represent $450 million in equity. In addition, eLong Power's majority shareholder is entitled to receive up to 9,000,000 ordinary shares of the combined company upon the achievement of certain revenue-based milestones during calendar years 2024 and 2025. At closing, any cash remaining in TMTC's trust account will be contributed to eLong Power to support ongoing operations and planned business expansion efforts. References to available cash from the TMTC trust account and retained transaction proceeds are subject to any redemption by the public shareholders of TMTC ordinary shares and payment of transaction fees and expenses. TMTC and eLong Power have agreed to work together to pursue commitments for a private placement of equity financings of up to $15 million. The transaction, which has been unanimously approved by both Boards of Directors of eLong Power and TMTC, is subject to approval by the shareholders of TMTC and other customary closing conditions. The proposed business combination is expected to be completed in the first half of 2024.

09:16 EST Twilio to cut about 5% of current workforce

09:09 EST Amylyx announces data showing effect of AMX0035 on biomarkers in ALS - Amylyx Pharmaceuticals announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis ALS from the Phase 2 CENTAUR trial. These findings were published in the peer-reviewed medical journal, Journal of Neurology, Neurosurgery and Psychiatry. During the CENTAUR trial, plasma samples were prospectively collected from trial participants for future biomarker analyses. Post hoc analyses were conducted to look at the impact of AMX0035 on biomarkers shown to correlate with ALS disease progression, including chitinase biomarkers such as YKL-40 , chitinase 1 CHIT1 , and the systemic inflammatory biomarker C-reactive protein . The results of these post hoc analyses demonstrated a significant reduction in plasma concentrations of YKL-40 and CRP, but not CHIT1, over 24 weeks, with reductions observed as early as Week 12 in participants from the CENTAUR trial. Of the 135 participants in the modified intent-to-treat population of the CENTAUR trial, 126 had plasma samples available for these analyses. The analyses showed that geometric least squares mean YKL-40 and CRP plasma concentrations were 10% and 17% lower, respectively, at Week 12 and approximately 20% and 30% lower, respectively, at Week 24 in the AMX0035 versus placebo group. YKL-40 and CRP concentrations correlated with ALSFRS-R total score and ALSFRS-R slope. Geometric LS mean CHIT1 plasma levels were not significantly different between treatment groups. Further analyses of neuroinflammatory biomarkers are planned in the ongoing Phase 3 PHOENIX trial to confirm these results.

09:08 EST NanoVibronix enters LOI with Apogepha to explore European distribution - NanoVibronix announced that it has entered into a non-binding letter of intent, or LOI, with Apogepha Arzneimittel in which both parties will analyze the potential for Apogepha to distribute NanoVibronix's premiere UroShield product in Germany and other European markets. With a history that dates back over 100 years, Apogepha has established itself as a high quality, dedicated specialist in the field of urology. Under the terms of the LOI, Apogepha will commence a comprehensive market evaluation on how UroShield fits into the pathway of care for patients with long term catheters. The goal of the LOI, and subsequent findings, will be for both NanoVibronix and APOGEPHA to better understand the feasibility of a distribution deal between both companies.

09:06 EST CarGurus finalizes acquisition of CarOffer - CarGurus announced it has completed the acquisition of CarOffer, purchasing the remaining minority equity interests for $75 million. Zach Hallowell, a seasoned digital wholesale market leader, has assumed the role of Chief Executive Officer, CEO, for CarOffer. "With this transaction complete, we believe we are well-positioned to accelerate our momentum in delivering solutions that streamline and enhance the dealer-to-dealer and consumer-to-dealer transaction experience," said Hallowell. "I look forward to leading the integration between the CarOffer and CarGurus teams to advance these goals for the benefit of our customers." CarGurus acquired a 51% interest in CarOffer in January 2021 and announced plans on November 7, 2023 to accelerate the purchase of the remaining stake with the intent of capturing growing product and data opportunities, along with other synergies between the two platforms. Together the companies plan to build innovative solutions that power CarGurus' development of a transaction-enabled platform that supports dealers and consumers through every stage of the automotive lifecycle.

09:05 EST Check Point announces partnership with Denver Broncos - Check Point Software Technologies announced that the Denver Broncos, a professional football club in the National Football League, depend on Check Point's cyber security portfolio to protect Empower Field at Mile High, the team and staff. With a combination of Check Point CloudGuard, Quantum and Harmony, the Broncos will leverage a unified platform that provides a single pane of glass to seamlessly protect their network, perimeter and cloud applications. "During games and concerts, we push up to 25 terabytes of WiFi data through the firewalls. We rely on Check Point to quarterback our security by proactively preventing cyberattacks from disrupting operations," said Russ Trainor, Senior Vice President of Information Technology at the Denver Broncos. Harmony Endpoint and CloudGuard provide the Broncos' IT team with the full visibility of the stadium's connected devices and cloud-based applications that is needed to deliver a seamless fan experience, while also driving efficiency for the team.

09:03 EST LPL Financial: Demetrios Paraskevopoulos joins RIA, custodial platforms - LPL Financial LLC announced today that financial advisor Demetrios Paraskevopoulos has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $230 million in advisory, brokerage and retirement plan assets, and joins LPL from Ameriprise. Based in Mineola, N.Y., Paraskevopoulos joined the financial services industry in 1995 right out of college. The son of Greek immigrants, he knew from an early age that he wanted to go into finance so he could help people work toward their American dream.

09:02 EST Scilex announces addition of ZTlido as preferred agent to Medicaid PDL - Scilex announced that the State of Tennessee added ZTlido as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.1 This change has the potential to improve access to ZTlido for all eligible patients which includes approximately 1,500,000 adult lives between the ages of 19 to 64.1 "As we continue our commitment to improving access for ZTlido(R), the addition of ZTlido to the Medicaid Preferred Drug List of the State of Tennessee is another important step in the expansion of the use of ZTlido throughout the U.S. Importantly, our diversified portfolio of leading pain management products allows us to offer patients complementary and standalone non-opioid pain management solutions," said Jaisim Shah, Chief Executive Officer and President of Scilex.

09:01 EST Precision Optics enters licensing pact for cystoscopy robotic surgery system - Precision Optics announced it has signed a production and technology license agreement with a leading surgical robotics company to supply a single-use endoscope assembly used in their cystoscopy robotic surgery system. The agreement arises following joint product development initiatives between the two companies over the past eighteen months, relying heavily on Precision Optics Corporation's unique micro-optics and digital imaging technologies. Production of the endoscope assembly is expected to occur at POC's facilities beginning in the next six to twelve months and to continue for the foreseeable future. Should our customer later decide, however, to transfer production to one of their facilities or to a third-party manufacturer, POC would support the transfer and reap the benefits under the agreement's multi-year royalty provisions governing manufacturing at non-POC facilities.

08:58 EST Neuronetics's NeuroStar TMS receives expanded regulatory approval in Japan - Neuronetics announced that the Pharmaceuticals and Medical Devices Agency in Japan has approved multiple proprietary innovations, which significantly advance the patient treatment experience with the NeuroStar TMS Therapy System for the treatment of major depressive disorder in Japan. The features covered in this approval include the NeuroStar 3.7 platform, MT Cap, D-Tect MT Accessory, and the Dash treatment protocol.

08:51 EST Jaguar Health says FDA approves renewal of Canalevia-CA1 - Jaguar Health announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1. Canalevia-CA1, the company's conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea in dogs, is available from multiple veterinary distributors in the U.S., including Chewy. The renewal for conditional approval is in effect until December 21, 2024.

08:49 EST Sellas Life Sciences says IDMC recommends continuation of Phase 3 REGAL trial - SELLAS Life Sciences Group announced a review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S in acute myeloid leukemia by the Independent Data Monitoring Committee. The IDMC performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The IDMC also requested that the survival database be updated immediately prior to the next IDMC meeting, which will take place in Q1 2024, and be provided to the IDMC for its review at the meeting. REGAL is a Phase 3 open-label registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy. The primary endpoint is overall survival. The IDMC is an independent group of medical, scientific, and biostatistics experts who are responsible for reviewing and evaluating patient safety and efficacy data for REGAL, and for monitoring quality and overall conduct to ensure the validity, scientific and clinical merits of the study. The IDMC charter provides for periodic reviews for safety, efficacy, and futility in addition to the interim and final analyses.

08:46 EST PodcastOne acquires multiyear rights to 'Rabia & Ellyn Solve the Case' - PodcastOne has acquired the exclusive multiyear sales and distribution rights to New York Times best-selling author and attorney Rabia Chaudry's and actress Ellyn Marsh's true crime genre podcast, Rabia & Ellyn Solve the Case.

08:43 EST Foremost Lithium appoints Mason to board of directors - Foremost Lithium Resource & Technology announced the appointment of Douglas Mason, a veteran public company mining executive, to its Board of Directors as an independent director, effective December 04, 2023. Doug has served as a senior officer and director of a number of public companies, bringing 30+ years of extensive capital markets experience to the Foremost Board of Directors, and having assisted in raising hundreds of millions of dollars for such public companies during his tenure with the same. Doug served previously as CEO, President and a director of Clearly Canadian Beverage Corporation, a producer of premium beverage products. In connection with Doug Mason's appointment, the Company has now granted him an incentive option to purchase an aggregate of 20,000 common shares of the Company at an exercise price of CAD $5.47 per common share, expiring three years from the date of grant.

08:41 EST Sunshine Biopharma moves principal office to New York City - Sunshine Biopharma announced that it has moved its headquarters to New York City. The Company's Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036. The Company will maintain a satellite office at its previous headquarters in Montreal at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 have not changed.

08:40 EST Enterprise and ONEOK extend fee waiver deal for ICE Midland WTI deliveries - Intercontinental Exchange (ICE) announced that Enterprise Products Partners (EPD) and ONEOK, Inc. (OKE) have extended their fee waiver arrangement between the Enterprise Crude Houston and Magellan East Houston terminals to transfer crude oil delivered through ICE's Midland WTI futures contract (HOU) until December 31, 2025. HOU futures had a record third quarter in 2023 with 672,681 contracts traded, with record average daily volume of 10,677 contracts. Each month, the HOU futures contract delivers approximately 5 million barrels of Midland WTI-quality crude. HOU has delivered approximately 71 million barrels of Midland WTI-quality crude since early 2022. Midland WTI crude oil also became deliverable into Dated Brent and the rest of the Brent complex earlier this year. "Extending the fee waiver for customers to move Midland WTI barrels they acquire through the HOU contract to the terminal of their choosing provides additional incentive to manage their Midland WTI exposure with the HOU contract," said Jeff Barbuto, Global Head of Oil Markets at ICE. "Open interest has spread down the curve to the end of 2025 and this additional optionality should really add to the development of this market."

08:39 EST Verb's MARKET.live adds five more retail brands to livestream platform - Verb Technologyannounces five more dynamic new brands have joined the MARKET.live platform this week. The recent completion of the Company's tech integrations with the ecommerce solutions powering thousands of vendors' existing ecommerce stores are expected to continue to drive demand from retailers eager to create new and additional distribution channels and affiliate relationships through MARKET.live. Brands, retailers and creators that join MARKET.live have the ability to broadcast livestream shopping events simultaneously on numerous social media channels, including TikTok, as well as on MARKET.live, reaching exponentially larger audiences.This week's newly onboarded vendors represent a diverse array of product categories, offering a comprehensive and exciting selection for MARKET.live's growing user base: The Newly Onboarded Brands: Tuxton; Blakhom; Poppy+Sage; Rad: Rad; VistaShops. The addition of these five brands underscores MARKET.live's commitment to expanding its portfolio with top-tier products and brands, ensuring a vibrant and ever-evolving selection for its discerning audience.

08:38 EST Atossa Therapeutics appoints Arezoo Mirad as senior medical director - Atossa Therapeutics (ATOS) announced the appointment of Dr. Arezoo Mirad as Senior Medical Director. Prior to joining Atossa, Dr. Mirad served as Medical Director for Corcept Therapeutics (CORT).

08:37 EST SP Plus awarded five-year contract at San Francisco airport - SP+ Corporation announced its five-year contract for ground transportation management, parking, and concierge/ambassador services at San Francisco International Airport, SFO, in San Mateo County, California. SP+ worked collaboratively and efficiently with the long-term and proven local ACBDE/MBE/WBE/LBE. At SFO, SP+ provides management and operation of public and employee parking facilities, seven days a week, 24 hours per day, including ground transportation, curbside management, valet services, employee parking, security, janitorial and engineering services. SP+ also provides reservations and revenue management at SFO with its AeroParker branded e-commerce platform that increases non-aeronautical revenues through its user-friendly pre-booked parking system. This online technology is available via mobile, tablets, and desktops. "Our relationship with SP+ began with just two employees at SFO in 2012. Through their mentorship and guidance, we are now ACDBE-certified and proudly work with SP+ at multiple installations," said Patricia Rodriguez, owner and managing partner, SF Parking, LLC. "I want to thank SFO and the City of San Francisco for truly embracing the small business program - we are proof that a small local business can grow through these opportunities, provide good union jobs and contribute to our community and local economy.

08:35 EST Smart for Life announces LOI to acquire manufacturer of vitamins, supplements - Smart for Life announced that it has executed a Letter of Intent, LOI, to acquire a state-of-the-art manufacturer of vitamins and supplements, which is expected to add an estimated $20 million of revenue on a pro forma basis over the next year. "This target acquisition brings significant manufacturing capabilities in the health and wellness sector and should be highly synergistic with our existing channels and brands," stated Darren Minton, CEO of Smart for Life. "In addition, the company is already audited by a top ten PCAOB accounting firm, which will significantly streamline the due diligence phase, in addition to the overall speed of the transaction. Moreover, we believe Smart for Life can achieve meaningful operating efficiencies by bringing additional capabilities in-house, making this acquisition highly accretive. We look forward to sharing additional information as we complete due diligence and definitive documentation over the coming weeks."

08:34 EST Beyond sets Cyber 5 sales record with revenue up 24% y/y - Beyond announced record sales performance for the "Cyber 5" period from Thanksgiving Day through Cyber Monday. The Company also announced that it has initiated a fixed cost restructuring plan targeting approximately $25 million of annualized reductions by early 2025. 2023 Cyber 5 sales were the largest in the Company's history. Estimated net revenue grew 24% year-over-year. On an aggregate basis, bedding, bath, kitchen and core furniture and decor categories delivered growth. Active customers at the end of the Cyber 5 period exceeded 5.3 million. The Company will continue to invest in building the customer file and taking back market share. Additionally, the Company is on its way to a multi-phase relaunch of Overstock.com to reignite historical top performing categories.

08:33 EST Alexandria Real Estate raises quarterly dividend to $1.27 from $1.24 per share - The dividend is payable on January 12, 2024 to shareholders of record on December 29, 2023.

08:32 EST Southwest Gas to pursue IPO of Centuri Holdings in spring/summer 2024 - Southwest Gas announced its intent to pursue an initial public offering of newly issued shares of Centuri Holdings in the spring/summer 2024. The Southwest Gas board of directors has determined that an IPO is the optimal path to advance the separation of Centuri Group as an independent utility infrastructure services company to maximize value for Southwest Gas shareholders. "We plan to move forward with an IPO of Centuri once we have onboarded a new CEO of Centuri to lead the business into its next chapter as an independent publicly-traded company. We are highly encouraged by the receptivity for the separation of Centuri as we seek to unlock value for Southwest Gas shareholders, and we look forward to Centuri's planned debut as a separate public company," said Karen Haller, President and CEO of Southwest Gas. Current Centuri CEO Paul Daily previously announced his plan to retire in 2024 after his successor has been identified and onboarded.

08:28 EST Exelixis, Arcus team on trial of zanzalintinib-AB521 combo to treat ccRCC - Exelixis( EXEL) and Arcus Biosciences (RCUS) announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor, TKI, in combination with AB521, an inhibitor of the transcription factor HIF-2, in patients with advanced solid tumors, including clear cell renal cell carcinoma, ccRCC. Exelixis is sponsoring STELLAR-009, and Arcus is co-funding the study and providing AB521 for use in the trial. Patient enrollment for STELLAR-009 is expected to begin before the end of 2023."We are excited to learn more about the potential effects of zanzalintinib plus Arcus' HIF-2 inhibitor, as these two molecules approach the inhibition of cancer cell proliferation and tumor angiogenesis from differing angles, and combination therapy may provide better outcomes than either therapy alone," said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. "We have a long-established commitment to advancing treatment options in kidney cancer, and we are eager to maximize the potential of zanzalintinib through this collaboration with Arcus and look forward to advancing the combination in the clinic."

08:27 EST Spetz enters advisory services agreement with Jade Ventures - SPETZ has entered into an advisory services agreement with Jade Ventures. Under the terms of the Agreement, Jade Ventures will serve as Spetz's exclusive advisor and will help facilitate introductions on behalf of Spetz to global telecommunications companies. Jade Ventures will work closely with the Spetz management team to identify and pursue strategic opportunities with telecommunications companies that will enable Spetz to expand its platform into new markets or extend its current reach through telecommunications services. The team at Jade Ventures comprises experienced telecommunications professionals with a proven track record of success in completing high-value transactions in the telecommunications sector. The Agreement includes an initial six-month exclusivity period with an option to extend for an additional six months. The parties have also agreed to a performance-based compensation structure that aligns their interests and ensures that Spetz's cash flow is not compromised at this stage.

08:23 EST Jeffs' Brands' Fort Products enters distribution agreement with EasyLure - Jeffs' Brands announced that its, wholly owned subsidiary Fort Products signed an exclusive distribution agreement with EasyLure, for the sale and distribution of its pest control solution, the Entopest Fruit Fly Attractant. This agreement marks a significant expansion of Jeffs' Brands' pest control portfolio into the agricultural sector and strengthens its position in the global agricultural solutions market. Pursuant to the distribution agreement, Fort will have exclusive rights to sell and distribute globally the Entopest Fruit Fly Attractant, an acclaimed pest control solution for its effectiveness and eco-friendliness.

08:20 EST Standard BioTools, SomaLogic announce date for special meetings of stockholders - Standard BioTools (LAB) and SomaLogic (SLGC) announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on October 4, 2023. Each company will hold its respective Special Meeting of Stockholders virtually at 12 p.m. ET on Thursday, January 4, 2024. The stockholders of record as of the close of business on November 29, 2023, will be entitled to vote at their respective Special Meetings of Stockholders. The merger remains on track to close in the first quarter of 2024, subject to approval by both companies' stockholders and satisfaction of other customary closing conditions.

08:19 EST Catalyst Pharmaceuticals appoints Kalb as CFO, announces other promotions - Catalyst Pharmaceuticals announced the appointment of Michael Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. He succeeds Alicia Grande, who will retire from the Company at the end of this year. Before joining the Company, Mr. Kalb served as Chief Financial Officer at Impel Pharmaceuticals. Additionally, the company is pleased to announce that effective on January 1, 2024, Dr. Steven Miller will be promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen will be promoted to Executive Vice President, Chief Commercial Officer.

08:18 EST Enviri's Harsco to present AgroSilicio fertilizer from recycled steel slag - Harsco Environmental, a division of Enviri, has been invited by the Brazilian state of Minas Gerais to present the business' newly developed ecoproduct, AgroSilicio, at this year's COP28 Climate Summit in the United Arab Emirates. "Leaders in Minas Gerais State, Brazil, are striving to balance industrial growth and sustainability," said Wender Alves, LATAM Regional President at Harsco Environmental. "It was a breakthrough when we realized that slag from steel production could be transformed into quality fertilizer for the Brazilian agriculture business. We are proud that this has helped significantly reduce the carbon footprint and are honored to present this on behalf of Minas Gerais State, Brazil, at the world's most important environmental forum."

08:15 EST Crimson Wine Group appoints Adam Howell as CFO - Crimson Wine Group (CWGL) has named Adam Howell as CFO. Howell will become a member of Crimson's executive team and will report directly to Jennifer Locke, CEO. Howell most recently served as Senior Vice President, Finance and Accounting, for the Duckhorn Portfolio (NAPA).

08:14 EST VCI Global, Evolve Capital forge collaboration to enhance market access - VCI Global unveils a strategic collaboration with Evolve Capital Advisory Private Limited. This collaboration seeks to cultivate a comprehensive avenue, providing companies with enhanced opportunities to facilitate capital markets access through public listings on NASDAQ or SGX. While acknowledging the unique strengths of various international exchanges, this collaboration seeks to provide companies with an optimal pathway to listing, including NASDAQ as a strategic option. The U.S. capital markets, renowned for their size, liquidity, and stability, offer an additional avenue for global issuers to access capital. The synergistic strengths of VCI Global and Evolve Capital aim to establish a versatile platform that caters to the evolving needs of businesses in today's dynamic market environment. This endeavour is further fortified by VCI Global's extensive consultancy experience, having played a pivotal role for numerous companies, especially in tandem with their listing endeavours on NASDAQ. "This collaboration proves timely, aligning with the escalating trend of companies, particularly those from this region, actively pursuing listings, notably on NASDAQ, a platform rapidly ascending in popularity. One of the primary incentives for selecting NASDAQ as the listing venue lies in its comparatively lower minimum prerequisites for qualification. Furthermore, the positive reception of its entirely electronic trading infrastructure is noteworthy among a diverse spectrum of traders," said Dato Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global.

08:12 EST Voip-Pal.com announces 'favorable' ruling in Locksmith case - VoIP-Pal.com announce on Thursday, November 30, 2023, after the completion of trial, the Eighth Judicial District Court for the State of Nevada, rendered its decision in favor of VoIP-Pal upon all claims in the case entitled Locksmith Financial Corporation vs. VoIP-Pal.com Inc., et al., Case No.: A-20-807745-C. On January 1, 2020, Locksmith Financial Corporation commenced the litigation against VoIP-Pal.com Inc., and its transfer agent, New Horizon Transfer Inc., alleging a failure to register the transfer of certain shares that had been originally issued to Locksmith in and around 2013. Locksmith further requested injunctive relief in the form of an order recognizing its legal right to transfer certain shares in question. Lastly, Locksmith demanded monetary damages for VoIP-Pal. Inc.'s failure to transfer the shares. After the conclusion of the trial, the court ruled that two previously issued certificates of VoIP-Pal.com stock are not owned by Locksmith Financial Corporation. The court further ruled that Locksmith had not met its burden with respect to any of its claims against VoIP-Pal or New Horizon Transfer, Inc., awarding no damages to Locksmith and specifically ruling that Locksmith take nothing as a result of the litigation. The Company is also announcing that since the November 1, 2023 announcement of the two new RBR continuation patent grants in India, Patent No.: 450851 and Patent No.: 450865 VoIP-Pal has been approached by representatives of potentially interested parties. They have scheduled to begin exploratory discussions.

08:11 EST Panbela Therapeutics announces publication of abstract on SBP-101, DFMO - Panbela Therapeutics announces the publication of preclinical data from studies of ivospemin, SBP-101, and eflornithine, DFMO, research in multiple myeloma. Data published in the November supplemental issue of the Journal Blood investigated the effects of polyamine inhibition by ivospemin and CPP-1X on myeloma cell lines growth and viability in vitro. Results showed that ivospemin and CPP-1X treatment significantly decreased cell proliferation and induced apoptosis in a panel of multiple myeloma cell lines. When ivospemin and CPP-1X were combined an almost complete abolition of cell growth occurred. These results demonstrate the anti-neoplastic potential of ivospemin and CPP-1X and offer a compelling rationale for its clinical development as a potentially promising treatment option for multiple myeloma. "We are excited to have initiated the studies evaluating our polyamine inhibitors ivospemin and CPP-1X in models of multiple myeloma. This work demonstrates that each agent alone and in combination with each other can decrease tumor cell growth and induce tumor cell death. Since the literature has demonstrated the relationship between polyamines and the immune system, this suggests that by adding our polyamine metabolic inhibitors, such as ivospemin and eflornithine, they may augment CAR-T cell therapy with the potential to overcome this resistance mechanism to potentially improve initial response rates and durability of response," said Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "Polyamine modulation of the immune system is an important focus for Panbela. With our first clinical proof of concept of polyamine targeted therapy in combination with a checkpoint inhibitor for patients with STK11 non-small cell lung cancer, we are excited for this research collaboration to now evaluate the potential benefit of polyamines in immune modulation for hematologic malignancies."

08:10 EST LuxUrban Hotels chairman cancels promissory note - LuxUrban Hotels (LUXH) announced that the company is in active late stage discussions with its partner, Wyndham Hotels & Resorts (WH), on various aspects of Development Incentive Advances, which include accelerating the timing and increasing the amounts of these funds on new property acquisitions. As a result of this anticipated positive development, on December 3, the company and Brian Ferdinand, the company's chairman and co-CEO, mutually agreed to cancel the previously disclosed promissory note dated November 17. Therefore, Ferdinand will cease, for the foreseeable future, further sales of common stock of the company that were to have been used to fund amounts borrowable under the promissory note. An amount equal to the proceeds resulting from recent sales by Ferdinand in the amount of approximately $500,000 will be gifted to the company.

08:08 EST Kanen CEO issues letter to eGain board of directors - Kanen Wealth Management CEO David Kanen send the board of directors of eGain a letter. "We, Kanen Wealth Management, LLC, owner of approximately 7% of eGain Corporation's common shares, are calling on the board to formally hire an investment banker and form a special committee to pursue a sale of the Company. Under CEO Ashu Roy's leadership, EGAN's stock is down approximately 40% since the Company's IPO 24 years ago in 1999 versus the NASDAQ gain of approximately 500%. The above scorecard speaks for itself! We will attempt to provide some insight into the various reasons we believe the Company has materially underperformed and how Mr. Roy is incapable, in our opinion, of realizing the potential of EGAN for shareholders, despite the Company's high-quality products, the Company's position in the "magic quadrant," and recent momentum in EGAN's sales funnel. We believe the problem is Ashu Roy and he has failed shareholders! Some examples of his arrogant, ineffective, and unsuccessful behavior for shareholders are below: failure in building a thriving sales organization... holding a major sales conference on yom kippur... ashu's obtuse, unengaged behavior with counterparties, when introductions were made earlier this year... improper handling of a recent introduction to a board candidate that is a proven software ceo and rockstar... In summary, EGAN directors, we ask that you kindly act on your fiduciary responsibility to shareholders and run a legitimate process to sell the company - a process that doesn't rely exclusively on Mr. Roy's lack of talent in generating a positive outcome. "

08:07 EST Texas Pacific Land announces Delaware Court of Chancery rules in its favor - Texas Pacific Land announced that the Delaware Court of Chancery has ruled in favor of TPL in the litigation between the company and Horizon Kinetics, Horizon Kinetics Asset Management, SoftVest Advisors and SoftVest, L.P., in Texas Pacific Land Corp. v. Horizon Kinetics LLC. On December 1, the court ruled that the investor group should have voted with the board's recommendation on Proposal 4, the company's proposal to increase the number of authorized shares of common stock at the 2022 annual meeting, under the terms of the June 2020 stockholders' agreement with the company. The court has deemed the investor group's shares to have been voted in favor of the Share Authorization Proposal, which has been deemed approved by stockholders.

08:06 EST Iterum Therapeutics regains compliance with Nasdaq bid price rule - Iterum Therapeutics has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

08:05 EST Yoshitsu announces launch of U.S. direct-store in Seattle - Yoshitsu announced the opening of its direct-sale store in the United States. The Store, set to open on December 8, 2023, will be located at 4514 University Way NE, Seattle, WA 98004, in the University District adjacent to the University of Washington. The Company believes that the opening of the Store marks a strategic step in its global market expansion. The Store, encompassing a floor area of 6,000 sq. ft. and featuring a range of over 8,000 stock keeping units, is situated near I-5 Express and U District light rail station. The Company believes that the location of the Store enhances its accessibility, and expects the Store to play an active part in local community events and activities. In addition, the store is expected to be uniquely designed to cater to customers in Seattle, with a focus on tech-related products. Mei Kanayama, the Principal Executive Officer of Yoshitsu, commented, "The opening of the Store in Seattle marks a milestone in our course of global expansion. We chose to open the Store in the University District, aiming to engage with diverse communities in Seattle. We are excited to bring our Japanese products to Seattle and look forward to becoming an integral part of the local community."

08:04 EST Cyclerion Therapeutics appoints Graul as President - Cyclerion Therapeutics announced that Regina Graul, Ph.D., has joined the company as president, effective immediately. As Cyclerion's president, she will lead the organization and will work closely with, and report directly to, the board of directors. She will be responsible for creating, implementing, and executing strategy as well as building a uniquely talented cross-functional management team. With Graul's arrival, transitional commitments under the asset purchase agreement with Tisento Therapeutics completed, and general expense reductions largely in place, founding chief executive officer Peter Hecht, Ph.D. has completed his transitional assignment. As a result, he is stepping away from an operational role at Cyclerion, effective immediately, and will continue to work with Dr. Graul and her team as a strategic consultant and board director going forward. Regina most recently served as vice president, program executive at EQRx, where she led cross-functional development teams in oncology, using the latest in clinical innovation to create and deliver sustainable solutions.

08:03 EST The Oncology Institute expands specialty medication business - The Oncology Institute announced that it has started operations of its first pharmacy in California after receiving approval from the California State Board of Pharmacy. This new service allows TOI to fill not only critical specialty medications and chemotherapeutics for MediCal patients, but also to provide medication fill capabilities to other patient populations. Located in the Los Angeles area, this new pharmacy location comes in addition to the multiple integrated specialty medication dispensaries that TOI already uses to manage oral and injectable medications. "We are ecstatic that we finally have the opportunity to significantly expand our oral drug business with this new pharmacy location," shared Chief Executive Officer, Dr. Daniel Virnich. "We are seeking to address the cancer care costs of hundreds of thousands of MediCal patients that we were unable to serve through our dispensaries. Now, we expect to be able to fill their medications more quickly and conveniently."

08:02 EST Ansys announces departure of CFO Nicole Anasenes - Ansys announced that Nicole Anasenes, CFO and senior vice president of finance, will depart the company in the second quarter of 2024. Ansys has launched a search for a new CFO, whom Anasenes will help to transition into the role.

08:00 EST Nayax appoints Moshe Shmaryahu as CIO - Nayax announced that Moshe Shmaryahu recently joined the Nayax leadership team as Chief Information Officer. Shmaryahu will lead the company's information systems and Corporate IT, uniting the IT internal infrastructure and business applications under one roof to optimize the organization's systems and technology. Shmaryahu, who began serving as Nayax's Chief Information Officer last month, served for 11 years prior to this as COO, Senior Director of Operations and Infrastructure at the Union Bank of Israel. In his new role, Shmaryahu will report directly to the CEO, Yair Nechmad, and will be part of the leadership team. Both Corporate IT and IS functions will report directly to Shmaryahu.

07:53 EST SL Green Realty, Vornado sign lease with tenant at 280 Park Avenue - SL Green Realty Corp. (SLG), and Vornado Realty Trust (VNO) announced that they have signed a 15-year renewal and expansion lease with a premier financial services tenant covering 269,905 square feet on six floors at 280 Park Avenue. Spanning the entire block front of Park Avenue between 48th and 49th Streets, 280 Park Avenue is a 1.25 million-square-foot Midtown Manhattan office building owned in joint venture between SL Green and Vornado.

07:39 EST Vision Marine Technologies enters partnership with Blue Water Boat Rental - Vision Marine Technologies announces a significant expansion in Riviera Beach, Florida this month through a strategic partnership with Blue Water Boat Rental. A central aspect of this expansion is introducing the E-Motion 180E Powertrain System to renters. "The opening of our first rental operation in Florida this month marks a significant milestone in our quest to transform the boating industry, and this is just the beginning," stated Alexandre Mongeon, CEO of Vision Marine.

07:37 EST Marimed commences operations of Illinois processing facility - MariMed has begun manufacturing and processing cannabis products in its new processing kitchen in Mt. Vernon, Illinois. After lengthy construction and regulatory delays, the Company expects that its award-winning products will be available at dispensaries in Illinois in time for the holidays. These include MariMed's five Thrive Dispensary-branded retail locations in the state. The processing facility contains an extraction lab to produce concentrates, and a production kitchen for the manufacture of edibles and other derivative products. The cultivation facility is currently under construction in the same facility and is expected to be completed in 2024. MariMed intends to manufacture and distribute its proprietary brands and products throughout Illinois. That includes its Betty's Eddies fruit chews, Bubby's Baked soft and chewy baked edibles, Vibations hydrating drink mix, InHouse gummies, K Fusion chewable tablets, and more. Upon completion of the cultivation facility construction the Company plans to commence selling its Nature's Heritage flower through retail and wholesale channels. MariMed operates five Thrive Dispensary locations in Anna, Casey, Harrisburg, Metropolis, and Mt. Vernon, Illinois.

07:35 EST Parsons, MSCI change Parsons' GICS code to research, consulting services - Parsons Corporation (PSN) announced that S&P Dow Jones Indices and MSCI (MSCI) recently changed the company's Global Industry Classifications Standard Code to Research and Consulting Services acknowledging the company's status as a leading professional services provider.

07:34 EST SL Green Realty board establishes annual ordinary dividend of $3.00 per share - SL Green Realty announced that its board of directors has established an annual ordinary dividend on SL Green's common stock of $3.00 per share. The ordinary dividend will continue to be paid in cash on a monthly basis. The first monthly ordinary dividend of $0.25 per share is payable on January 16, 2024, to stockholders of record at the close of business on December 29, 2023.

07:33 EST CME Group reached ADV of 28.3M contracts in November - CME Group reported its November 2023 market statistics, reaching an average daily volume of 28.3M contracts during the month, an increase of 21% over 2022 and the company's highest-ever November ADV on record. Reference Link

07:32 EST Saia reports November LTL shipments per workday increased 18.9% YoY - Saia is providing LTL shipment and tonnage data for the first two months of the fourth quarter. In October 2023, LTL shipments per workday increased 18.0%, LTL tonnage per workday increased 7.8% and LTL weight per shipment declined 8.6% to 1,321 pounds. In November 2023, LTL shipments per workday increased 18.9%, LTL tonnage per workday increased 9.2% and LTL weight per shipment declined 8.1% to 1,313 pounds.

07:31 EST CTO Realty Growth announces sale of three single tenant outparcels for $9.2M - CTO Realty Growth announced the closing of the sale of three single tenant outparcels in Chandler, Arizona for a combined sales price $9.2 million, representing a weighted average exit cap rate of 5.9% and generating aggregate gains on sale of approximately $3.0 million. The outparcels are leased to Olive Garden, Old Chicago Pizza + Taproom, and Mattress Firm and were part of the Company's Crossroads Towne Center property. "We're pleased with the attractive pricing we received on these property sales, as these dispositions continue our efforts to sell smaller format properties to paydown debt as we search for higher growth, larger format investment opportunities," said John P. Albright, President and Chief Executive Officer of CTO Realty Growth, Inc. "Our year-to-date dispositions cap rate of 6.4% is accretive to the $64 million of debt we recently repaid, which had an in-place floating rate of 7.1%, and also compares favorably to the yield on our most recent acquisition located in a growing submarket of Dallas, Texas."

07:24 EST Brad Jacobs to lead equity investment of $1B in SilverSun Technologies - SilverSun Technologies and Jacobs Private Equity II, which is led by Brad Jacobs, announced that they and minority co-investors have entered into an investment agreement, pursuant to which JPE and the minority co-investors will invest $1 billion in cash into SilverSun. The proposed equity investment is comprised of $900 million by JPE and $100 million by co-investors, including Sequoia Heritage. Upon the closing of the equity investment, JPE will become the majority stockholder of SilverSun and Jacobs will become the Company's chief executive officer and chairman of its board of directors. The Investment Agreement also provides for the spin-off of the Company's existing business to SilverSun stockholders as of a record date that is expected to be one day prior to the closing of the investment. The remaining Company will become a standalone platform for significant acquisitions in an industry to be announced soon, along with the company's new name. Under the terms of the Investment Agreement, the Company will, shortly after the closing of the investment, separate the existing SilverSun business as SilverSun Technologies Holdings and distribute all shares of the spin-off company to the stockholders of SilverSun as of a record date that is expected to be one day prior to the closing of the equity investment. The Company will also effect an 8:1 reverse stock split prior to the closing of the equity investment. Upon the closing of the investment and the effectiveness of the reverse stock split, JPE, Sequoia Heritage and the other co-investors will have: voting, convertible preferred stock that, in aggregate, is convertible into approximately 219 million shares of the Company's common stock at a price of $4.57 per share; and warrants to purchase an additional approximately 219 million shares of the Company's common stock at post-reverse-split exercise prices of: $4.57 per share with respect to 50% of the warrants, $6.85 per share with respect to 25% of the warrants, and $13.70 per share with respect to the remaining 25% of the warrants. Following the closing of the investment, JPE and the co-investors will own approximately 99.85% of the Company's common stock on a fully convertible/exchangeable basis. In addition, SilverSun will declare a $2.5 million aggregate cash dividend to its stockholders as of the same record date, to be funded from proceeds received under the Investment Agreement. The transactions contemplated by the Investment Agreement have been approved by SilverSun's board of directors, and are expected to be completed in 2024. The transactions are subject to SilverSun stockholder approval and the satisfaction of other customary closing conditions. The Company's current management and board of directors, including Mark Meller, SilverSun's chief executive officer, are expected to continue in their current roles at the spin-off company and its subsidiaries. The spin-off company will apply for a public listing of its shares, which will be registered pursuant to a Form 10 registration statement that will be filed with the U.S. Securities and Exchange Commission.

07:20 EST Brookfield to evaluate next steps with respect to Origin Energy - Brookfield Asset Management (BAM), together with its listed affiliate Brookfield Renewable Partners (BEP), acknowledges the announcement today by Origin Energy (OGFGF) of the result of Origin's shareholder vote in respect of the previously announced Scheme of Arrangement with Brookfield, its institutional investors, and EIG. Origin's shareholders voted 69% in favor of the transaction, which was short of the required 75% approval level required. In light of the result of the vote, Brookfield will evaluate its next steps, if any, with respect to Origin, given the strong level of Origin shareholder support for its proposal and taking into account the potential impact to Origin of the Australian Government's recently announced proposed expansion to its Capacity Investment Scheme and National Energy Transformation Partnership. "We are seeing plentiful opportunities to deploy capital at or above our target returns, as demand for clean power from corporations continues to accelerate and access to capital is becoming increasingly scarce for some market participants. We remain confident that we will deploy at least $7 to $8 billion of equity capital into growth over the next five years, consistent with our targets," said Connor Teskey, CEO Brookfield Renewable. "Specifically, our plan to accelerate the transition of Origin has generated significant interest from similar businesses around the world, who are seeking a capital and operating partner to enhance the value of their businesses by accelerating their transition."

07:17 EST Emerita Resources files supporting documentation for exploitation license - Emerita Resources announces that through its wholly-owned Spanish subsidiary, Emerita Resources Espana S.L.U., it has submitted all the required documentation to support its application to the "Delegacion Territorial de Energia y Minas in Huelva province, Junta de Andalucia" for an exploitation licence for Emerita's wholly-owned Iberian Belt West project. The Supporting Documentation includes all technical aspects for mining and processing at the IBW Project, as well as associated infrastructure, equipment and tailings storage facilities in order to build and operate a mine; and a restoration plan. Although the Exploitation Licence application and Supporting Documentation is thorough with all technical aspects of the Project necessary to receive the appropriate approvals from the Spanish authorities, it has not been prepared in compliance with National Instrument 43-101 and, consequently, economics for the Project cannot be disclosed at this time. The Supporting Documentation, including the environmental parameters, basic engineering, along with a revised mineral resource estimate incorporating new drill results, will comprise the basis for a NI 43-101 compliant economic study in the first half of 2024. The Exploitation Licence in Spain, when granted, has a 30-year term and can be extended for two subsequent 30-year periods.

07:16 EST TScan Therapeutics appoints McCue as Chief Technology Officer - TScan Therapeutics announced the appointment of Justin McCue, Ph.D., as its Chief Technology Officer. Dr. McCue joins TScan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products. Dr. McCue joins TScan from Avectas, a cell engineering technology company, where he most recently served as Chief Technology Officer responsible for leading technology development and scientific strategy.

07:15 EST Okyo Pharma announces last patient enrolled in OK-101 trial - OKYO Pharma announces the last patient of a planned 240-patient double-blind placebo-controlled phase 2 clinical trial of OK-101 to treat DED has completed the 12-week OK-101 dosing study. In addition, data analysis plans for the trial have now been finalized and submitted to FDA for feedback, in anticipation of database lock, subsequent data analysis, and reporting of top-line findings on OK-101. "With the final patient visit now completed in the phase 2 DED trial, we remain on track with the release of top-line results in December of this year," said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. "OK-101 has been shown in pre-clinical animal studies to display dual-action anti-inflammatory and neuropathic corneal pain-reducing activities and we are eagerly awaiting the results of this first clinical trial of OK-101 in patients to assess the drug's potential to treat DED."

07:13 EST Lithium Ionic appoints Paulo Guimaraes Misk as COO - Lithium Ionic announced the appointment of Paulo Guimaraes Misk, as COO to lead the development of the Bandeira Lithium Project, in Minas Gerais State, Brazil. As an industry leader, Mr. Misk will strengthen the Company's executive team and its technical and operational capabilities as it quickly accelerates the Bandeira project. Prior to joining Lithium Ionic, Paulo held several executive and operational roles at Largo Inc. between 2014-2023, including President and COO, and most recently CEO and board member.T he Company also announces that Mr. Misk has been awarded 150,000 stock options to purchase common shares of the Company pursuant to the Company's Stock Option Plan. The Options are exercisable to purchase common shares of the Company at an exercise price of $1.60 per common share for a period of five years expiring on December 1, 2028. The grant of Options is subject to approval of the TSX Venture Exchange.

07:10 EST Oxford Biomedica to acquire ABL Europe from Institut Merieux - Oxford Biomedica entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Merieux, for the acquisition of ABL Europe SAS. This follows the announcement on 20 September 2023, of exclusive negotiations in relation to the proposed acquisition by Oxford Biomedica of ABL Europe, a pure-play European CDMO with specialised expertise in the development and manufacturing of solutions for biotechs and biopharma including viruses for gene therapy, oncolytic viruses and vaccine candidates, in exchange for Oxford Biomedica ordinary shares. The acquisition of ABL Europe will consolidate Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space. It will broaden the Company's international presence by establishing a footprint within the European Union through facilities located in Lyon and Strasbourg, France. In addition, the acquisition will increase Oxford Biomedica's capacity in process and analytical development and early-stage manufacturing and address increased client demand for process development. ABL Europe currently works on more than 10 cell and gene therapy programmes spanning disease areas including more than six different vector types. Forecasted revenues for ABL Europe for the year ending 31 December 2023 are c.EUR 15 million. Institut Merieux has acquired a 3.3 per cent stake in Oxford Biomedica, through purchases in the open market, which it intends to increase to approximately 10.0 per cent in aggregate by the end of Q3 2024. Completion of the Transaction is currently expected to take place in the first quarter of 2024 subject to the satisfaction and/or waiver of outstanding conditions, including obtaining the necessary regulatory approvals. Upon Completion, the Transaction is expected to be immediately revenue accretive to Oxford Biomedica. Further financial guidance will be provided after Completion. As at 31 December 2022, ABL Europe had earnings before interest tax and depreciation of c.EUR (1.7)m and gross assets of c.EUR 23.6m. The Transaction constitutes a Class 2 transaction for the Company for the purposes of the UK Financial Conduct Authority's Listing Rules. As previously disclosed, key details of the Transaction follow below: Acquisition of ABL Europe by Oxford Biomedica for a consideration of EUR 15 million, to be satisfied by the issue of new ordinary shares in the Company. The Consideration Shares will be issued at a price being the higher of 407.4 pence per share equating to the 6-month volume weighted average price. to market close on 19 September 2023; and the VWAP between 19 September 2023 and the second trading day before the date of Completion. Applications will be made for the Consideration Shares to be admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc. Commitment from Institut Merieux to provide the Company with EUR 20 million of additional funding, to cover capital expenditure and potential operational losses in relation to the acquisition of ABL Europe, by means of an equity subscription in the Company, with timing at Oxford Biomedica's discretion prior to 27 September 2024. Pursuant to the Deferred Equity Subscription, Institut Merieux will provide the additional funding by the end of Q3 2024, or such earlier date requested by Oxford Biomedica subject to 10 business days prior notice to Institut Merieux, in exchange for Oxford Biomedica ordinary shares.The Deferred Subscription Shares will be issued at a price being the 30-day VWAP to closing on the second business day before the Deferred Subscription Date.

07:09 EST Chimerix promotes LaSpaluto to Chief Financial Officer - Chimerix announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023. Since joining Chimerix in 2011, LaSpaluto has served in roles of increasing responsibility spanning finance, accounting, project planning, investor relations and strategy, most recently as Vice President Corporate Financial Planning and Investor Relations.

07:07 EST RedHill Biopharma announces new non-dilutive external funding - RedHill Biopharma announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

07:07 EST Trevena announces TRV045 presentation at ACNP meeting - Trevena announced a poster presentation at the 62nd Annual Meeting for the American College of Neuropsychopharmacology, ACNP. The conference is being held from December 3rd to 6th, 2023. The poster discussed the potential utility of TRV045 for the treatment of chemotherapy-induced peripheral neuropathy using an established nonclinical model. CIPN is a nerve-damaging side effect of antineoplastic agents and occurs in approximately 70% of oncology patients undergoing chemotherapy. In addition, the Company is currently collaborating with the National Institutes of Health, NIH, to evaluate TRV045 for the potential treatment of epilepsy and as a nonopioid treatment for pain. "These are compelling nonclinical findings for TRV045 that add to our growing understanding of its mechanism and the potential use in a range of CNS disorders, including neuropathic pain," said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena.

07:05 EST Apollomics presents interim data from ongoing Phase 2 trials with vebreltinib - Apollomics announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial and the ongoing global multi-cohort Phase 2 SPARTA trial at the 2023 IASLC North America Conference on Lung Cancer, that was held December 1-3, 2023, in Chicago, Illinois. Vebreltinib appears efficacious in non-small cell lung cancer patients with MetExon14 skipping mutation with or without co-occurring MET amplification. Of the 83 NSCLC patients with MetExon14 skipping mutation with available gene copy number data from the Phase 2 KUNPENG and SPARTA trials, 91.6% did not have co-occurring MET amplifications, reflecting the real-world distribution of the NSCLC patients with MetExon14 skipping mutation from two large public databases. NSCLC patients with MetExon14 skipping mutation without co-occurring MET amplification from the KUNPENG and SPARTA trials showed an overall response rate of 64.5% and a median duration of response of 15.9 months, and those with overlapping MET amplification achieved ORR of 85.7%. To date, more than 500 patients and 170 healthy volunteers have been dosed with vebreltinib. The safety profile is generally acceptable. Preliminary efficacy and safety data from the Phase 2 KUNPENG and SPARTA trials in patients with MetExon14 skipping mutation is presented in poster PP01.104 titled, "Vebreltinib Efficacy In MetEx14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases." The preliminary data from NSCLC patients with MetExon14 skipping mutation from the KUNPENG and SPARTA trials showed the following efficacy and safety results: ORR in patients without co-occurring MET amplification was 64.5%, with median DOR of 15.9 months and Disease Control Rate of 88%. ORR in patients with MET amplification was 85.7%, with DCR of 100%. mDOR was not reached. There were only 2 patients with GCNgreater than or equal to6, and both achieved partial response. Treatment-related adverse events of grade 3 or higher were reported in 42.2% of patients, with the most common being edema and ALT increase. Of NSCLC patients with MetExon14 skipping mutation with available GCN data included in this analysis, 91.6% had no co-occurring MET amplification, similar to 83.6% and 91.9% in two public databases.

07:03 EST EyePoint announces EYP-1901 achieved primary endpoints in Phase 2 trial - EyePoint Pharmaceuticals announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. The clinical trial met its primary endpoint with both EYP-1901 doses demonstrating statistical non-inferiority change in best corrected visual acuity compared to aflibercept control and a favorable safety profile with no EYP-1901-related ocular or systemic serious adverse events. The trial also achieved key secondary endpoints with both EYP-1901 doses, including an over 80% reduction in treatment burden, nearly two-thirds of eyes supplement-free up to six months and over 80% receiving only zero or one supplement up to six-months. Additionally, there was strong anatomical control with both EYP-1901 cohorts as measured by optical coherence tomography. DAVIO 2 topline interim results include: Both EYP-1901 doses achieved all primary and secondary endpoints. Statistical non-inferiority in change in BCVA compared to aflibercept control, at weeks 28 and weeks 32 combined. The 2mg and 3mg doses were only -0.3 and -0.4 letters different, respectively, versus on-label aflibercept. The lower limit of the non-inferiority margin is defined as a -4.5 letters by the FDA with 5 letters representing one line on the eye chart. Continued positive safety and tolerability profile with no EYP-1901-related ocular or systemic SAEs. 89% and 85% reduction in treatment burden, respectively, for the 2mg and 3mg EYP-1901 doses. 65% and 64% of eyes were supplement free up to six-months, respectively, for the 2mg and 3mg doses of EYP-1901. Both EYP-1901 doses demonstrated strong anatomic control with OCT difference below 10 microns at week 32 compared to the aflibercept control. Patient discontinuation up to week 32 was low at 4%.

07:02 EST 89bio reaches alignment with FDA, EMA on Phase 3 pegozafermin program - 89bio announced a successful end-of-Phase 2 Meeting with the U.S. Food & Drug Administration supporting the advancement of pegozafermin into Phase 3 in NASH. The program will include two Phase 3 trials evaluating patients with NASH: ENLIGHTEN-Cirrhosis will enroll patients with compensated cirrhosis and ENLIGHTEN-Fibrosis will enroll patients with fibrosis stage F2-F3. The F2-F3 and the F4 trials are expected to initiate in the first quarter and the second quarter of 2024, respectively. Initial scientific advice received from EMA was generally aligned with the feedback from the FDA. The planned ENLIGHTEN program will be comprised of two randomized, double-blinded, placebo-controlled Phase 3 trials, evaluating the efficacy and safety of pegozafermin in patients with NASH. ENLIGHTEN-Cirrhosis, in patients with compensated F4 NASH: The trial will evaluate the efficacy and safety of pegozafermin administered 30mg weekly. Histology Portion: The primary endpoint will be regression of fibrosis from F4 to an earlier stage of fibrosis. This endpoint is planned to be assessed at 24 months, with the potential to assess it earlier based on the evolving clinical and regulatory landscape. This primary endpoint is intended to support a filing for accelerated approval in the United States and conditional approval in Europe in F4 patients. Outcome Portion: Patients will continue to be treated in a blinded extension phase through clinical outcome events that are expected to be predominantly decompensation events. Alignment with the FDA on modified definitions of some of these events could allow the trial to reach the final number of events more quickly and therefore accelerate the timeline to trial readout. Positive results would support full approval in F4 patients and will also serve as confirmatory full approval in F2-F3 patients. ENLIGHTEN-Fibrosis, in patients with F2-F3 NASH: The trial will evaluate the efficacy and safety of pegozafermin administered 30mg weekly and 44mg every-two-weeks. Histology Portion: The co-primary endpoints will be a one-point improvement in fibrosis with no worsening of NASH and NASH resolution with no worsening of fibrosis. These endpoints will be assessed at week 52 and are intended to support a filing for accelerated approval in the U.S. and conditional approval in Europe in F2-F3 patients. Outcome Portion: Patients will continue to be treated in a blinded extension phase to measure clinical outcomes to support full approval in F2-F3 patients. The clinical outcome events are expected to be primarily due to progression to cirrhosis. Both ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis will enroll a significant proportion of patients on stable doses of GLP-1 based therapies and data from these patients in the trials will evaluate the expected incremental benefit of adding pegozafermin to these therapies. Both trials will employ the three-panel consensus biopsy reading methodology, which was successfully utilized in the ENLIVEN trial, for both baseline and primary endpoint biopsy reads. Patients will self-administer pegozafermin using the planned commercial liquid formulation delivered as a single subcutaneous injection.

07:01 EST Eli Lilly extends tender offer to acquire Point Biopharma - Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Point Biopharma (PNT) for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

06:39 EST U.S. DFC signs LOI considering $500M loan to VinFast Auto - Within the framework of COP28, VinFast Auto and the United States International Development Financial Corporation have signed a letter of Interest to consider a formal application by VinFast for a $500M loan to establish a lithium-ion battery manufacturing facility in Vietnam. The signing not only reaffirms both parties' commitment to fostering sustainable transportation, but also marks a significant milestone in the Vietnam - U.S. Comprehensive Strategic Partnership. DFC and VinFast will further discuss and consider VinFast's formal application for a $500M loan for the establishment of its lithium-ion battery manufacturing facilities in Vietnam, subject to DFC's comprehensive review and approval process. This is the first project in a series of sustainable transportation development initiatives in the Vietnamese and international markets being actively discussed by the two parties.

06:31 EST Carbon Revolution awarded program by premium brand of major German automaker - Carbon Revolution announced that it has been awarded a program by a premium brand of a major German automaker, one of two previously announced OEM wheel programs awarded in recent months. Overall, the company has been awarded 18 vehicle programs for six global OEMs including Ford Motor Company, General Motors Company, Renault, Ferrari N.V. and Jaguar Land Rover and intends to continue to expand its portfolio of global automaker clients as demand grows for its disruptive efficiency technology.

06:28 EST Roche to buy Carmot Therapeutics for $2.7B upfront, up to $400M in milestones - Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned U.S. company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs. "The existing clinical data for Carmot's assets, especially the lead asset CT-388, suggests a best-in-class potential to achieve and maintain weight loss with differentiated efficacy. Moreover, the assets provide an opportunity for combinations with existing Roche pipeline assets including ones focused on other benefits, such as preserving muscle mass. Incretins are gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite. The incretin-based portfolio could also be expanded to other indications where incretins play a role including cardiovascular, retinal and neurodegenerative disease," Roche stated. Under the terms of the agreement, Roche will pay Carmot's equity holders a purchase price of USD 2.7 billion in cash at the closing of the transaction. Additionally, Carmot's equity holders are entitled to receive payments of up to USD 400 million depending on the achievement of certain milestones. Upon closing of the transaction, Roche will obtain access to Carmot's current R&D portfolio including all clinical and pre-clinical assets, with Carmot and its employees joining the Roche Group as part of Roche's Pharmaceuticals Division. Upon closing of the transaction, Roche will also have exclusive access to Carmot's innovative Chemotype Evolution discovery platform in metabolism to further strengthen Roche's R&D efforts and portfolio across cardiovascular and metabolic diseases. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. The closing of the transaction is currently expected to take place in the first quarter of 2024. Reference Link

06:11 EST Spotify to cut employee base by approximately 17% - In a regulatory filing, Spotify announced a reduction in the company's employee base by approximately 17%. As a result, the company estimates that it will incur approximately EUR 130M- EUR 145M in charges in the fourth fiscal quarter of 2023, primarily consisting of severance-related payments and the impairment of real estate assets as a part of optimizing the company's office space footprint in connection with the reduction in the employee base, partially offset by forfeitures of equity awards by departing employees. The majority of the cash component of these charges will occur over the first and second fiscal quarters of 2024. The company anticipates that these actions will generate meaningful operating efficiencies going forward. Due to the charges, the company is updating its operating income outlook for the fourth fiscal quarter of 2023 to a range of (EUR 108M)- (EUR 93M).

06:06 EST Veon's Kyivstar,Amazon Web Services sign memorandum of cooperation - Veon (VEON) announces that Kyivstar, its subsidiary in Ukraine,will partner with Amazon Web Services (AMZN) to support Ukrainian businesses with the next generation of cloud and cloud infrastructure services and expertise in data-processing. As part of the Memorandum of Cooperation that the parties have signed, Kyivstar, as an AWS Partner, will provide its business clients with accelerated cloud migration of applications, computing, and data storage solutions, along with enhanced security measures through a range of AWS technologies-based services, as an AWS Partner.

06:04 EST Golden Heaven announces three strategic initiatives - Golden Heaven announced the following three strategic initiatives intended to accelerate the company's business expansion and bolster its presence in the market. The first initiative seeks to collaborate with top players in the Chinese amusement park industry and extend the Company's reach in the market. The second initiative will endeavor to increase the company's brand recognition, by learning from the successes of renowned global theme parks, such as creating exclusive IPs and promoting themed events. The third initiative contemplates the elevation of guest experiences of the company's service offerings by offering additional services, such as dining options and hotel lodging services in the parks.

06:02 EST Ideaya Biosciences enters clinical study pact, supply agreement with Gilead - Ideaya Biosciences (IDYA) announced it has entered into a clinical study collaboration and supply agreement with Gilead Sciences (GILD) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's sacituzumab-govitecan-hziy, a Trop-2 directed antibody-drug conjugate, or ADC, in a Phase 1 clinical trial. Under the clinical study collaboration and supply agreement, Gilead will provide drug supply to Ideaya, which will be the sponsor of the Phase 1 clinical combination trial. Ideaya and Gilead each retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.

05:54 EST Meta Platforms expands child safety features - Meta announced Friday that it has updated its child safety features after a series of Wall Street Journal reports, including expanding its list of terms, phrases, and emojis related to child safety. Meta said: "We take recent allegations about the effectiveness of our work very seriously, and we created a task force to review existing policies; examine technology and enforcement systems we have in place; and make changes that strengthen our protections for young people, ban predators, and remove the networks they use to connect with one another. The task force took immediate steps to strengthen our protections, and our child safety teams continue to work on additional measures." Reference Link

05:39 EST LexinFintech appoints Zhanwen Qiao as chief risk officer - LexinFintech announced that its board of directors has appointed Zhanwen Qiao as the company's chief risk officer, effective on December 4. Zhanwen Qiao has over a decade of experience. Prior to joining Lexin, Qiao served as a senior director at Ant Group and deputy general manager of Chongqing Ant Consumer Finance.

05:21 EST Rio Tinto approves new solar farm, battery storage to power Amrun operations - Rio Tinto has approved a new 12.4MW solar farm and 8.8MVa/2.1MWh of battery storage to provide renewable energy for the Amrun bauxite operations near Weipa in Queensland. The 12.4MW solar farm and battery storage are part of Rio Tinto's global decarbonisation strategy and ongoing efforts to reduce emissions at its Pacific bauxite, alumina and aluminium operations. They are expected to reduce Amrun's diesel electricity consumption by 37 percent and annual CO2-equivalent emissions by 14,000 tonnes, and will add to the existing 5.6MW of solar and 4MWh of battery power built for Rio Tinto's Weipa operations and the local electricity network since 2015. Aggreko has been contracted to build, own, and operate the solar farm to supply renewable electricity to the mine operations, in addition to its current contract to supply electricity generated from an existing diesel power station. Rio Tinto Weipa Operations General Manager Shona Markham said "The construction of the Amrun solar farm and battery storage system, which is located on Wik and Wik-Waya Traditional lands, is an important milestone for Weipa Operations and will contribute to Rio Tinto's commitment to reduce operational greenhouse gas emissions.

05:15 EST Guardant Health, Cancer Research Horizons collaborate to advance cancer research - Cancer Research UK, its innovation unit, Cancer Research Horizons, and Guardant Health announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity's research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development. This includes the DETERMINE trial - the first UK national precision medicine trial in rare cancers, and other Cancer Research UK and Cancer Research Horizons research collaborations. Additional potential collaboration activities may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant's technologies, as well as explore other projects to accelerate the discovery and development of cancer drugs and diagnostics.